174 related articles for article (PubMed ID: 37955612)
1. Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers.
Velez G; Wolf J; Dufour A; Mruthyunjaya P; Mahajan VB
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):14. PubMed ID: 37955612
[TBL] [Abstract][Full Text] [Related]
2. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
[TBL] [Abstract][Full Text] [Related]
4. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
5. [New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics].
Wen DJ; Ren XJ; Dong LJ; He Y; Li XR
Zhonghua Yan Ke Za Zhi; 2019 Oct; 55(10):769-776. PubMed ID: 31607066
[No Abstract] [Full Text] [Related]
6. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
8. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
9. Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status.
Rusakevich AM; Schefler AC; Zhou B; Brown A; Robe C; Bretana ME
Ophthalmic Surg Lasers Imaging Retina; 2022 Jul; 53(7):374-378. PubMed ID: 35858230
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
11. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
13. Liquid biopsy proteomics of uveal melanoma reveals biomarkers associated with metastatic risk.
Velez G; Nguyen HV; Chemudupati T; Ludwig CA; Toral M; Reddy S; Mruthyunjaya P; Mahajan VB
Mol Cancer; 2021 Feb; 20(1):39. PubMed ID: 33627107
[No Abstract] [Full Text] [Related]
14. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile.
Harbour JW
Methods Mol Biol; 2014; 1102():427-40. PubMed ID: 24258991
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomic analysis of human plasma using tandem mass tags to identify novel biomarkers for herpes zoster.
Wang T; Shen H; Deng H; Pan H; He Q; Ni H; Tao J; Liu S; Xu L; Yao M
J Proteomics; 2020 Aug; 225():103879. PubMed ID: 32585426
[TBL] [Abstract][Full Text] [Related]
16. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications.
Ragusa M; Barbagallo C; Statello L; Caltabiano R; Russo A; Puzzo L; Avitabile T; Longo A; Toro MD; Barbagallo D; Valadi H; Di Pietro C; Purrello M; Reibaldi M
Cancer Biol Ther; 2015; 16(9):1387-96. PubMed ID: 25951497
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Aqueous Humor Proteome Predicts Metastatic Potential in Uveal Melanoma.
Peng CC; Sirivolu S; Pike S; Kim ME; Reiser B; Li HT; Liang G; Xu L; Berry JL
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047796
[TBL] [Abstract][Full Text] [Related]
18. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
19. Proteomics in uveal melanoma.
Heiferman MJ; Mahajan VB; Mruthyunjaya P
Curr Opin Ophthalmol; 2022 May; 33(3):202-210. PubMed ID: 35102096
[TBL] [Abstract][Full Text] [Related]
20. Integrated differential DNA methylation and gene expression of formalin-fixed paraffin-embedded uveal melanoma specimens identifies genes associated with early metastasis and poor prognosis.
Ness C; Katta K; Garred Ø; Kumar T; Olstad OK; Petrovski G; Moe MC; Noer A
Exp Eye Res; 2021 Feb; 203():108426. PubMed ID: 33387485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
